Discovery & history

• Why adding a glucagon arm to GLP-1 changes what the drug can do
• How survodutide is engineered for once-weekly dosing
• What the obesity and MASH trials actually measured, tier by tier
• How it compares with semaglutide, tirzepatide, retatrutide, and cagrilintide
• How to read its investigational status, dosing framing, and safety honestly

1. 01 Discovery & history The obesity drug that borrows a second hormone free
2. 02 Chemistry, structure & pharmacokinetics How a glucagon backbone becomes a once-weekly drug paid
3. 03 Dual GLP-1 and glucagon receptor mechanism Two receptors, two organs, one weekly signal paid
4. 04 The glucagon advantage What the second hormone actually buys you paid
5. 05 Obesity: the weight-loss evidence From a dose-finding trial to a Phase 3 result paid
6. 06 MASH: the liver evidence The liver data that made survodutide stand out paid
7. 07 The clinical trial program How survodutide was tested, step by step paid
8. 08 The incretin landscape: how it compares Where survodutide sits among the metabolic drugs paid
9. 09 Regulatory status and the road ahead Investigational today, and what comes next paid
10. 10 Dosing & administration How survodutide is dosed in trials, for education only paid
11. 11 Safety & tolerability What is known about safety, and what is not paid
12. 12 Final Exam & Certification Pass the final exam to earn your specialist certificate. exam

Survodutide did not appear from nowhere. The body already makes a natural dual GLP-1 and glucagon agonist called oxyntomodulin, and in 2009 two labs showed that engineering one molecule to hit both receptors could reverse obesity in mice far beyond either hormone alone. That insight kicked off the modern co-agonist field, and survodutide is its most advanced Western obesity program.

Read the timeline as a slow build from a mouse experiment to a human obesity trial. The concept is 15 years old, but the clinical proof arrived only recently, and much of the Phase 3 program is still running. That gap between an old idea and young human data is a theme this course keeps returning to.

Strip away the branding and survodutide is a 29-amino-acid peptide built on a glucagon scaffold, with a fatty-acid tail bolted on so it lasts about a week in the body. It is dosed as a once-weekly injection under the skin. The two cards below anchor the basic numbers and put its headline weight loss beside the drugs it is measured against.

The bars show survodutide as a genuine obesity drug that lands close to semaglutide but below tirzepatide and retatrutide on raw weight loss. That ranking matters: survodutide is not the strongest number in the class, so its case rests on a different mechanism, not a bigger dose, which the next page unpacks.

The whole point of survodutide is that its two receptor arms do different work. The GLP-1 arm handles the familiar appetite and blood-sugar effects shared by every drug in this class. The glucagon arm adds something GLP-1 alone cannot: a direct signal to the liver to burn fat and spend more energy. The two panels lay the arms side by side.

Holding both arms in view prevents the most common mistake about survodutide: treating it as a slightly stronger semaglutide. It is not stronger, it is additive in a different direction. The comparison that matters is glucagon versus tirzepatide GIP, not one dose against another, a distinction this course builds on throughout.

Survodutide sits in an unusual spot: strong Phase 2 data and one positive Phase 3 obesity readout, but no approval, no cardiovascular outcome trial finished, and no long-term safety record. The honest ceiling keeps those apart. What is genuinely well supported today is narrower than the online enthusiasm suggests, and the four tiers below separate proven from promising from purely hoped-for.

A handful of claims dominate the online conversation about survodutide. Held against the actual trials, most are not simply false so much as overstated: a real effect gets rounded up or stripped of its qualifier. Tap each claim to see the honest verdict and its evidence tier, and notice how often the fix is a number or a caveat rather than a flat yes or no.

The recurring theme is proportion, not truth. Survodutide really does lower weight and improve liver biopsies; the distortion is one of size, certainty, and availability. Learning to attach the right qualifier to a real effect is the core literacy skill this course builds, and it matters most for a drug people are hearing about before they can legally get it.